Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caplacizumab in acquired thrombotic thrombocytopenic purpura
NCT01151423Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jan 2011
- Primary completion
- Mar 2014
- Countries
- 13
01
Overview
Phase 2, randomised trial in thrombotic thrombocytopenic purpura (TTP) comparing Caplacizumab + PE with Placebo + PE (2 arms). Primary endpoint: Time-to-response of Treatment Defined by a Confirmed Recovery of Platelets ≥ 150,000/µL at 30 days. Started Jan 2011; status: completed.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT01151423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151423.